Perrigo Company Overview
- Founded
-
1887

- Status
-
Public
- Employees
-
9,900

- Stock Symbol
-
PRGO

- Investments
-
49
- Share Price
-
$37.38
- (As of Monday Closing)
Perrigo Company General Information
Description
Perrigo Co PLC is a leading private label supplier of generic over the counter (OTC) drugs in the U.S. and Europe. The company's product offerings fall under traditional OTC drug categories (i.e. cough, cold, allergy, pain), in addition to oral care, infant nutrition (formula), and nicotine cessation aids. In addition to private label manufacturing, the company also sells products under its own brands (largely in the skincare and oral-care category). The company became a pure-play in OTC consumer healthcare in 2021, following a series of divestitures over several years (sold off generic prescription topicals, animal health, and active pharmaceutical ingredient business). In late 2021, Perrigo signed an offer to acquire HRA Pharma.
Contact Information
- The Sharp Building
- Hogan Place
- Dublin 2
- Ireland
Perrigo Company Stock Performance
(As of Monday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$37.38 | $37.20 | $30.78 - $43.90 | $5.03B | 135M | 1.51M | -$0.80 |
Perrigo Company Financials Summary
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 8,432,078 | 6,676,004 | 8,814,691 | 10,133,322 |
Revenue | 4,401,200 | 4,138,700 | 4,088,200 | 3,869,900 |
EBITDA | 345,600 | 680,500 | 421,300 | 562,600 |
Net Income | (107,300) | (68,900) | (162,600) | 146,100 |
Total Assets | 10,677,500 | 10,425,700 | 11,488,400 | 11,301,400 |
Total Debt | 4,111,000 | 3,693,800 | 3,725,700 | 3,369,200 |
Perrigo Company Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Perrigo Company Comparisons
Industry
Financing
Details
Perrigo Company Competitors (32)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Abbott India | Corporation | Mumbai, India | 0000 | |||
0000-0 00000 00000 | Corporate Backed or Acquired | Seoul, South Korea | 00 | 000000000 | ||
000000000000000 00 | Corporation | Lagos, Nigeria | 00 | |||
00000000 | Corporation | Winnipeg, Canada | 00 | 00000 | 000000000 | 00000 |
000000 00000000000 | Corporation | Montreal, Canada | 000 | 00000 | 00000000 | 00000 |
Perrigo Company Patents
Perrigo Company Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20210113698-A1 | Bulk polyethylene glycol compositions | Pending | 18-Oct-2019 | 000000000 | 0 |
US-20210023073-A1 | Dextromethorphan extended release pharmaceutical composition | Pending | 22-Jul-2019 | 0000000000 | 0 |
US-D904182-S1 | Carton | Active | 29-Jun-2018 | ||
US-D874261-S1 | Carton | Active | 29-Jun-2018 | ||
US-D904181-S1 | Carton | Active | 29-Jun-2018 |
Perrigo Company Executive Team (40)
Perrigo Company Board Members (12)
Name | Representing | Role | Since |
---|---|---|---|
0000000 0000000000 | Self | Board Member | 000 0000 |
000000 0000000 | Self | Board Member | 000 0000 |
0000000 000000 | Perrigo Company | Board Member | 000 0000 |
00000 0000 | Self | Board Member | 000 0000 |
00000000 000000 | Self | Board Member | 000 0000 |
Perrigo Company Signals
Perrigo Company Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Perrigo Company Investments & Acquisitions (49)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
000000 (00000 | 01-Nov-2022 | 000000000 | 00000 | Buildings and Property | |
000 000000 | 29-Apr-2022 | 0000000000 | 00.000 | Drug Discovery | 000000 00 |
000000 (00000 | 02-Nov-2020 | 000000000 | Buildings and Property | 000000 00 | |
0000000 | 17-Jun-2020 | 000000000 | 0000 | Other Pharmaceuticals and Biotechnology | 000000 00 |
High Ridge Brands (Oral Care Assets) | 01-Apr-2020 | Merger/Acquisition | 00000 | Personal Products | 000000 00 |
Perrigo Company Subsidiaries (5)
Company Name | Industry | Location | Founded |
---|---|---|---|
Vedants Drugs and Fine Chemicals | Pharmaceuticals | Mumbai, India | 2004 |
000 000000 | Drug Discovery | Paris, France | 0000 |
0000000 000000000 | Pharmaceuticals | Balcatta, Australia | 0000 |
00000 | Other Commercial Products | Grand Rapids, MI | 0000 |
0000000 0000000000 | Drug Delivery | Ciudad Satelite, Mexico | 0000 |
Perrigo Company ESG
Risk Overview
Risk Rating
Updated September, 11, 2022
36.74 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,613
Rank
Percentile

Pharmaceuticals
Industry
00 of 1,004
Rank
Percentile

Pharmaceuticals
Subindustry
00 of 472
Rank
Percentile

Perrigo Company Exits (5)
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
00000000-00000 000 | 28-Aug-2015 | 000000000000000000 | 000.00 | Completed |
|
00000000 000000000 | 11-Feb-2013 | 000000000000000000 | 00000 | Completed |
|
000 000000 0000000 | 01-Jan-2003 | 000000000000000000 | Completed |
|
|
000000 | 01-Jan-1997 | 000000000000000000 | Completed |
|
|
Vi-Jon | 01-Dec-1994 | Merger/Acquisition | 0000 | Completed |